Gynipral (Hexoprenaline Sulfate)

Gynipral is a prescription medication that contains the active ingredient hexoprenaline sulfate, supplied as an intravenous injectable solution. It belongs to the beta‑2 adrenergic agonist class and is marketed in the European Union for obstetric use. The drug acts on uterine smooth muscle to facilitate tocolysis, helping to manage preterm labor. It is administered under supervision and is not intended for self‑medication.

Gynipral is indicated for obstetric situations where inhibition of uterine contractions is required, particularly in the management of preterm labor and related conditions.

- Acute preterm labor to delay delivery for corticosteroid administration. - Tocolysis during threatened preterm birth when other agents are contraindicated. - Suppression of uterine activity during certain obstetric procedures. - Management of uterine hyperstimulation after oxytocin infusion. - Short‑term use in clinical trials evaluating novel tocolytic strategies.

The pharmacologic action of hexoprenaline sulfate can produce a range of adverse effects, which are generally categorized by frequency and severity.

Common: - Transient tachycardia or palpitations. - Mild tremor of the hands or limbs. - Headache or dizziness. - Flushing of the face and neck.

Serious: - Significant hypotension or cardiovascular collapse. - Severe bronchospasm in patients with reactive airway disease. - Fetal distress indicated by abnormal heart rate patterns.

Because Gynipral influences smooth muscle tone and cardiovascular function, several precautions should be observed before and during therapy.

- Verify maternal cardiovascular status; avoid use in uncontrolled hypertension. - Assess for a history of cardiac arrhythmias or ischemic heart disease. - Use cautiously in patients with asthma or chronic obstructive pulmonary disease. - Monitor fetal heart rate continuously during infusion. - Limit duration of therapy; prolonged use may increase risk of adverse outcomes. - Ensure appropriate dosing under specialist supervision; do not exceed recommended infusion rates.

Hexoprenaline sulfate may interact with other medications, altering its efficacy or increasing the risk of adverse events.

Avoid: - Concurrent use with non‑selective beta‑blockers, which can blunt the tocolytic effect. - Combination with other potent vasodilators that may precipitate severe hypotension.

Use with caution: - Co‑administration with magnesium sulfate, as additive uterine relaxation may occur. - Concurrent use of sympathomimetic agents (e.g., epinephrine) that could enhance cardiovascular stimulation. - Caution when given with inhaled bronchodilators, as additive beta‑2 activity may increase tremor.